(PDF) Cambridge, UK – The not-for-profit Open PHACTS Foundation announced its first three members today – GlaxoSmithKline, Janssen and Roche – who will steer the future of the successor organisation to the Innovative Medicines Initiative (IMI)- funded Open PHACTS project.
The commitment by these global pharmaceutical industry members signifies a major step in ensuring the sustainability of infrastructure developed during the Open PHACTS project.
The Open PHACTS community covering academia, industry, application developers and semantic web experts has delivered a powerful cloud-based data platform, demonstrating the effectiveness of robust data integration in answering real scientific questions.
As a leading IMI project, the Open PHACTS project has built a sustainable succession plan through the Foundation to both continue provision of the Open PHACTS Discovery Platform and to extend the coverage of data and functionality. Collaboration with existing and future consortia will engage the scientific community and involve relevant applied life science R&D.
The Open PHACTS Discovery Platform offers free access to its suite of APIs which connect biology, chemistry and disease information from public data sets. Built to answer key questions from the pharmaceutical industry, the integrated data is available to the scientific and developer community
“The unrivalled triumph of Open PHACTS and the data integration infrastructure developed by the project highlights the benefits of effective scientific community collaboration. The engagement that the Foundation has seen from pharmaceutical companies is testimony to the value of the project.”
Professor Gerhard Ecker, University of Vienna
The Open PHACTS Foundation
The Open PHACTS Foundation is a not-for-profit membership organisation, supporting the Open PHACTS Discovery Platform developed during the Open PHACTS project. The Open PHACTS Foundation is registered in the United Kingdom.
The Open PHACTS project
The project has and developed the Open PHACTS Discovery Platform to answer key scientific questions for applied life science R&D. The current 31 member consortium features academic and pharmaceutical industrial partners, and has developed an additional community of application developers and smaller enterprises to use the Open PHACTS Discovery Platform to meet the needs of drug discovery scientists.
The Open PHACTS project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115191, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.